Office of National Drug Control Policy: Reauthorization Hearing, Before the Committee on Oversight and Government Reform, Subcommittee on Government Operations, U.S. House of Representatives, One Hundred Fourteenth Congress, First Session, December 2, 2015 [open pdf - 2MB]
This is a testimony compilation of the December 2, 2015 hearing "Office of National Drug Control Policy: Reauthorization" held before the House Committee on Oversight and Government Reform. From the testimony of the Director of the Office of National Drug Control Policy (ONDCP), Michael Botticellii: "As you know, ONDCP was established by Congress under the Anti-Drug Abuse Act of 1988, with the principal purpose of reducing illicit drug use, manufacturing, and trafficking; drug-related crime and violence; and drug-related health consequences. November 2015 marked the 27th anniversary of ONDCP, and the Office was most recently reauthorized by the Office of National Drug Control Policy Reauthorization Act of 2006. As a component of the Executive Office of the President, ONDCP establishes policies, priorities, and objectives for the Nation's drug control programs and ensures that adequate resources are provided to implement them. We also develop, evaluate, coordinate, and oversee the international and domestic anti-drug efforts of Executive Branch agencies and, to the extent practicable, ensure such efforts complement state and local drug policy activities. In addition, we are charged with producing the 'National Drug Control Strategy (Strategy)', the Administration's primary blueprint for drug policy, along with a national drug control budget." Statements, letters, and other materials submitted for the record include those of the following: Michael Botticelli, David Kelley, and David Maurer.
U.S. House Committee on Oversight and Government Reform: https://oversight.house.gov/